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In their paper, Castleberry et al (2009) propose an economic
approach, which estimates cost-effectiveness in terms of the cost
per 5-year survivor instead of per year of life gained. This is an
interesting approach in oncology, in which clinical results are very
often presented as 5-year survival rates. It also raises interesting
issues. For example, the inbuilt advantage to preventing deaths
earlier in life when using the cost per year of life saved will be
less pronounced with the proposed measure. The methodology of
estimation is rigorous and painstaking. The controversial aspect
of Castleberry et al’s work is the application of their approach
to CT screening for lung cancer. The survival of screen-detected
cases is known to be potentially affected by self-selection for
screening, lead-time bias, length bias, and its extreme form,
overdiagnosis.
It is the last potential bias that is probably the most important
issue in Castleberry et al’s evaluation of lung cancer screening. A
long-term follow-up of the Mayo Lung Project suggests that there
is an element of overdiagnosis in conventional chest X-ray
screening for lung cancer (Marcus et al, 2006). Owing to its
greater sensitivity, it is difficult to avoid the conclusion that there
must be some overdiagnosis in CT screening.
The time to death from lung cancer in patients with the disease
is likely to be a mixture of continuous distributions, as is the time
to death from other causes. It is inevitable that in some cases the
latter occurs before the former, and that in some screen-detected
cases the latter will occur before the date on which the disease
would have been symptomatically diagnosed. This brings us to the
observation that overdiagnosis has an epidemiological rather than
pathological definition. It is defined as the diagnosis by screening
of a disease that would never have been clinically diagnosed in the
lifetime of the host had screening not taken place.
The above definition does not refer to the pathological attributes of
at u m o u r ,b u ti n t u i t i v e l y ,o n ew o u l d expect overdiagnosed cases of any
cancer to be largely characterised by favourable stage, type, and other
pathological factors. The discussion of overdiagnosis in the context of
lung cancer has tended to focus on the suspicion that there is a
substantial proportion of screen-detectable cancers that have little or
no potential to cause symptoms or threaten life (Dammas et al,2 0 0 1 ) .
A number of randomised trials of CT screening for lung cancer
are in progress, and there is a possibility of these being augmented
by a trial in the UK. Only such randomised trials will be able to
establish the existence of a mortality benefit and, if relevant,
estimate its size. They will also help to inform us about the
existence and magnitude of overdiagnosis. One aspect of this that
has been neglected is that if the hypothesis of a sizeable population
of indolent lung tumours is correct, this is a fascinating
phenomenon, given the very poor prognosis of symptomatic
disease. If such a population exists, the challenges will be to find
pathological or biological markers to identify it, and to research
interventions that will make the remaining lung tumour popula-
tion behave in the same benign manner.
The primary purpose of the CT screening trials is of course
to inform us of its efficacy. In the absence of such trial results, any
cost-effectiveness estimates are inevitably speculative, assuming a
life year’s benefit that has not yet been proven. Preliminary
estimates may, however, be of some use in planning till the time
the trial results are available. However, such estimation should
take account of the important potential biases, for which methods
are available (Duffy et al, 2008). Further arithmetic adjustment in
addition to the analysis of Castleberry et al may seem to be a
daunting prospect. For credible results, however, addressing the
potential biases is absolutely necessary.
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